FDA Releases Guidance on Critical Path Innovation Meetings
FDA outlines procedures for having a Critical Path Innovation Meeting with CDER.
FDA has released draft guidance on the purpose, scope, documentation, and administrative procedures for a Critical Path Innovation Meeting (CPIM). The guidance includes how to request such a CPIM meeting, which is the way the Center for Drug Evaluation and Research (CDER) and investigators from industry, academia, patient advocacy groups, and government can communicate to improve efficiency and success in drug development.
A CPIM may be used as a way for industry to discuss a methodology or technology with CDER so that CDER may identify gaps in existing knowledge that requesters might consider addressing in the course of their work. According to FDA, discussions and background information submitted through the CPIM are nonbinding on both FDA and CPIM requesters.
The guidance provides some examples of topics appropriate for a CPIM. It also describes information that should be provided to CDER in preparation for a meeting and potential outcomes from the CPIM.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
